Literature DB >> 23372056

Mutations in the X-linked retinitis pigmentosa genes RPGR and RP2 found in 8.5% of families with a provisional diagnosis of autosomal dominant retinitis pigmentosa.

Jennifer D Churchill1, Sara J Bowne, Lori S Sullivan, Richard Alan Lewis, Dianna K Wheaton, David G Birch, Kari E Branham, John R Heckenlively, Stephen P Daiger.   

Abstract

PURPOSE: We determined the fraction of families in a well-characterized cohort with a provisional diagnosis of autosomal dominant retinitis pigmentosa (adRP) that have disease-causing mutations in the X-linked retinitis pigmentosa GTPase regulator (RPGR) gene or the retinitis pigmentosa 2 (RP2) gene.
METHODS: Families with a provisional clinical diagnosis of adRP, and a pedigree consistent with adRP but no male-to-male transmission were selected from a cohort of 258 families, and tested for mutations in the RPGR and RP2 genes with di-deoxy sequencing. To facilitate testing of RPGR in "adRP" families that had no male members available for testing, the repetitive and purine-rich ORF15 of RPGR was subcloned and sequenced in heterozygous female subjects from 16 unrelated families.
RESULTS: Direct sequencing of RPGR and RP2 allowed for identification of a disease-causing mutation in 21 families. Of these "adRP" families 19 had RPGR mutations, and two had RP2 mutations. Subcloning and sequencing of ORF15 of RPGR in female subjects identified one additional RPGR mutation. Of the 22 mutations identified, 15 have been reported previously.
CONCLUSIONS: These data show that 8.5% (22 in 258) of families thought to have adRP truly have X-linked retinitis pigmentosa (XLRP). These results have substantive implications for calculation of recurrence risk, genetic counseling, and potential treatment options, and illustrate the importance of screening families with a provisional diagnosis of autosomal inheritance and no male-to-male transmission for mutations in X-linked genes. Mutations in RPGR are one of the most common causes of all forms of retinitis pigmentosa.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23372056      PMCID: PMC3597192          DOI: 10.1167/iovs.12-11541

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  36 in total

1.  The Gly56Arg mutation in NR2E3 accounts for 1-2% of autosomal dominant retinitis pigmentosa.

Authors:  Anisa I Gire; Lori S Sullivan; Sara J Bowne; David G Birch; Dianna Hughbanks-Wheaton; John R Heckenlively; Stephen P Daiger
Journal:  Mol Vis       Date:  2007-10-17       Impact factor: 2.367

2.  Mutations in known genes account for 58% of autosomal dominant retinitis pigmentosa (adRP).

Authors:  Stephen P Daiger; Lori S Sullivan; Anisa I Gire; David G Birch; John R Heckenlively; Sara J Bowne
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

3.  A dominant mutation in RPE65 identified by whole-exome sequencing causes retinitis pigmentosa with choroidal involvement.

Authors:  Sara J Bowne; Marian M Humphries; Lori S Sullivan; Paul F Kenna; Lawrence C S Tam; Anna S Kiang; Matthew Campbell; George M Weinstock; Daniel C Koboldt; Li Ding; Robert S Fulton; Erica J Sodergren; Denis Allman; Sophia Millington-Ward; Arpad Palfi; Alex McKee; Susan H Blanton; Susan Slifer; Ioanna Konidari; G Jane Farrar; Stephen P Daiger; Peter Humphries
Journal:  Eur J Hum Genet       Date:  2011-06-08       Impact factor: 4.246

4.  The retinitis pigmentosa GTPase regulator (RPGR) interacts with novel transport-like proteins in the outer segments of rod photoreceptors.

Authors:  R Roepman; N Bernoud-Hubac; D E Schick; A Maugeri; W Berger; H H Ropers; F P Cremers; P A Ferreira
Journal:  Hum Mol Genet       Date:  2000-09-01       Impact factor: 6.150

5.  Severe manifestations in carrier females in X linked retinitis pigmentosa.

Authors:  E Souied; B Segues; I Ghazi; J M Rozet; S Chatelin; S Gerber; I Perrault; A Michel-Awad; M L Briard; G Plessis; J L Dufier; A Munnich; J Kaplan
Journal:  J Med Genet       Date:  1997-10       Impact factor: 6.318

6.  Genomic rearrangements of the PRPF31 gene account for 2.5% of autosomal dominant retinitis pigmentosa.

Authors:  Lori S Sullivan; Sara J Bowne; C Robyn Seaman; Susan H Blanton; Richard A Lewis; John R Heckenlively; David G Birch; Dianna Hughbanks-Wheaton; Stephen P Daiger
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-10       Impact factor: 4.799

7.  Spectrum of mutations in the RPGR gene that are identified in 20% of families with X-linked retinitis pigmentosa.

Authors:  M Buraczynska; W Wu; R Fujita; K Buraczynska; E Phelps; S Andréasson; J Bennett; D G Birch; G A Fishman; D R Hoffman; G Inana; S G Jacobson; M A Musarella; P A Sieving; A Swaroop
Journal:  Am J Hum Genet       Date:  1997-12       Impact factor: 11.025

8.  Identification of an intronic single-point mutation in RP2 as the cause of semidominant X-linked retinitis pigmentosa.

Authors:  Esther Pomares; Marina Riera; Joaquín Castro-Navarro; Angeles Andrés-Gutiérrez; Roser Gonzàlez-Duarte; Gemma Marfany
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-06-10       Impact factor: 4.799

9.  Mutation analysis of the RPGR gene reveals novel mutations in south European patients with X-linked retinitis pigmentosa.

Authors:  M G Miano; F Testa; M Strazzullo; M Trujillo; C De Bernardo; B Grammatico; F Simonelli; M Mangino; I Torrente; G Ruberto; M Beneyto; G Antinolo; E Rinaldi; C Danesino; V Ventruto; M D'Urso; C Ayuso; M Baiget; A Ciccodicola
Journal:  Eur J Hum Genet       Date:  1999-09       Impact factor: 4.246

10.  Functional analysis of retinitis pigmentosa 2 (RP2) protein reveals variable pathogenic potential of disease-associated missense variants.

Authors:  Suresh B Patil; Toby W Hurd; Amiya K Ghosh; Carlos A Murga-Zamalloa; Hemant Khanna
Journal:  PLoS One       Date:  2011-06-27       Impact factor: 3.240

View more
  64 in total

1.  A long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration.

Authors:  Zhijian Wu; Suja Hiriyanna; Haohua Qian; Suddhasil Mookherjee; Maria M Campos; Chun Gao; Robert Fariss; Paul A Sieving; Tiansen Li; Peter Colosi; Anand Swaroop
Journal:  Hum Mol Genet       Date:  2015-04-15       Impact factor: 6.150

2.  The ophthalmic experience: unanticipated primary findings in the era of next generation sequencing.

Authors:  Jillian T Huang; John R Heckenlively; K Thiran Jayasundera; Kari E Branham
Journal:  J Genet Couns       Date:  2014-01-08       Impact factor: 2.537

Review 3.  Gene therapy and genome surgery in the retina.

Authors:  James E DiCarlo; Vinit B Mahajan; Stephen H Tsang
Journal:  J Clin Invest       Date:  2018-06-01       Impact factor: 14.808

4.  Disruption of RPGR protein interaction network is the common feature of RPGR missense variations that cause XLRP.

Authors:  Qihong Zhang; Joseph C Giacalone; Charles Searby; Edwin M Stone; Budd A Tucker; Val C Sheffield
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-08       Impact factor: 11.205

5.  Loss of RPGR glutamylation underlies the pathogenic mechanism of retinal dystrophy caused by TTLL5 mutations.

Authors:  Xun Sun; James H Park; Jessica Gumerson; Zhijian Wu; Anand Swaroop; Haohua Qian; Antonina Roll-Mecak; Tiansen Li
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-09       Impact factor: 11.205

6.  Loss of human disease protein retinitis pigmentosa GTPase regulator (RPGR) differentially affects rod or cone-enriched retina.

Authors:  Kollu N Rao; Linjing Li; Wei Zhang; Richard S Brush; Raju V S Rajala; Hemant Khanna
Journal:  Hum Mol Genet       Date:  2016-01-24       Impact factor: 6.150

7.  Loss of retinitis pigmentosa 2 (RP2) protein affects cone photoreceptor sensory cilium elongation in mice.

Authors:  Linjing Li; Kollu Nageswara Rao; Yun Zheng-Le; Toby W Hurd; Concepción Lillo; Hemant Khanna
Journal:  Cytoskeleton (Hoboken)       Date:  2015-10-14

8.  Molecular Findings in Families with an Initial Diagnose of Autosomal Dominant Retinitis Pigmentosa (adRP).

Authors:  Stephen P Daiger; Sara J Bowne; Lori S Sullivan; Kari Branham; Dianna K Wheaton; Kaylie D Jones; Cheryl E Avery; Elizabeth D Cadena; John R Heckenlively; David G Birch
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

9.  Four-year placebo-controlled trial of docosahexaenoic acid in X-linked retinitis pigmentosa (DHAX trial): a randomized clinical trial.

Authors:  Dennis R Hoffman; Dianna K Hughbanks-Wheaton; N Shirlene Pearson; Gary E Fish; Rand Spencer; Alison Takacs; Martin Klein; Kirsten G Locke; David G Birch
Journal:  JAMA Ophthalmol       Date:  2014-07       Impact factor: 7.389

10.  Optimization of Retinal Gene Therapy for X-Linked Retinitis Pigmentosa Due to RPGR Mutations.

Authors:  William A Beltran; Artur V Cideciyan; Shannon E Boye; Guo-Jie Ye; Simone Iwabe; Valerie L Dufour; Luis Felipe Marinho; Malgorzata Swider; Mychajlo S Kosyk; Jin Sha; Sanford L Boye; James J Peterson; C Douglas Witherspoon; John J Alexander; Gui-Shuang Ying; Mark S Shearman; Jeffrey D Chulay; William W Hauswirth; Paul D Gamlin; Samuel G Jacobson; Gustavo D Aguirre
Journal:  Mol Ther       Date:  2017-05-27       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.